Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Receivables - Other: 2020-2024

Historic Receivables - Other for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Dec 2024 value amounting to $1.3 million.

  • Tarsus Pharmaceuticals' Receivables - Other rose 49.87% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 49.87%. This contributed to the annual value of $1.3 million for FY2024, which is 18.85% up from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Receivables - Other of $1.3 million as of FY2024, which was up 18.85% from $1.1 million recorded in FY2023.
  • In the past 5 years, Tarsus Pharmaceuticals' Receivables - Other ranged from a high of $3.6 million in FY2022 and a low of $20,000 during FY2020.
  • Moreover, its 3-year median value for Receivables - Other was $1.3 million (2024), whereas its average is $2.0 million.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Receivables - Other surged by 1,691.00% in 2022, and later crashed by 69.49% in 2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' Receivables - Other (Yearly) stood at $20,000 in 2020, then skyrocketed by 900.00% to $200,000 in 2021, then surged by 1,691.00% to $3.6 million in 2022, then tumbled by 69.49% to $1.1 million in 2023, then grew by 18.85% to $1.3 million in 2024.